Getinge Announces U.S. Commercial Availability of iCast Covered Stent System for Treatment of Iliac Arterial Occlusive Disease
Today Getinge announced commercial availability of the iCast covered stent system in the United States for the treatment of iliac arterial occlusive disease. In March 2023, the iCast covered stent received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of iliac arterial occlusive disease. Lower extremity peripheral artery disease (PAD) is estimated to affect approximately 8.5 million people in the U.S. per year [[[1]]][,[[2]]].“We are very pleased that the iCast covered stent is now available to clinicians and hospital systems throughout the U.S. for